Skip to content

Released Nov 8, 2022, after the close

10-Q filed Nov 9, 2022, 40 days after period end · 0001162194-22-000098

Q3 2022 · 10-Q
Revenue$25.65M−10.0% vs Q3 2021+36.6% vs Q2 2022
Net Income-$29.43MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.37N/M vs Q3 2021N/M vs Q2 2022
Gross Profit$9,220,000—
Operating Income-$29,027,000N/M
Operating Cash Flowderived-$24,611,000N/M
Free Cash Flowderived-$25,875,000N/M
Margins · derived
Gross margin36.0%
Operating margin-113.2%−44.4 pt vs Q3 2021
Net margin-114.7%−66.2 pt vs Q3 2021

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$25.65M$28.50M$39.86M$26.50M
Net Income-$29.43M-$13.84M-$6.00M-$12.89M
EPS Diluted-$0.37-$0.18-$0.08-$0.19

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR